Leanne J Kosse

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 8

Top Topics

Top Venues

Expert opinion on drug safety

This page only lists publications with an associated author ORCID identifier.

Publications

Janneke M Quik, Helen R Gosselt, Jette A van Lint, Leanne J Kosse, Peter M Ten Klooster, Harald E Vonkeman, Bartholomeus J F van den Bemt, Naomi T Jessurun
The burden of adverse drug reactions reported by patients in the Dutch ADR monitor: a proof of concept. Expert opinion on drug safety (2024)
Benthe H König, Helen R Gosselt, Jette A van Lint, Leanne J Kosse, Bartholomeus J F van den Bemt, Peter M Ten Klooster, Harald E Vonkeman, Naomi T Jessurun
Quantification of longitudinal patient-reported burden of adverse drug reactions attributed to the use of TNF-α inhibitors in inflammatory rheumatic diseases: an observational prospective cohort study. Expert opinion on drug safety (2024)
Kimberly Velthuis, Naomi T Jessurun, Thi D M Nguyen, Joep H G Scholl, Jurriaan R G Jansen, Jette A van Lint, Leanne J Kosse, Peter M Ten Klooster, Harald E Vonkeman
First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treatment with adalimumab and etanercept. Expert opinion on drug safety (2023)
Helen R Gosselt, Jette A van Lint, Leanne J Kosse, Phyllis I Spuls, Harald E Vonkeman, Sander W Tas, Frank Hoentjen, Michael T Nurmohamed, Bart J F van den Bemt, Martijn Bastiaan Adriaan van Doorn, Naomi T Jessurun
Sex differences in adverse drug reactions from adalimumab and etanercept in patients with inflammatory rheumatic diseases. Expert opinion on drug safety (2023)
Kimberly Velthuis, Naomi T Jessurun, Thi D M Nguyen, Joep H G Scholl, Jurriaan R G Jansen, Jette A van Lint, Leanne J Kosse, Peter M Ten Klooster, Harald E Vonkeman
First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treatment with adalimumab and etanercept. Expert opinion on drug safety (2023)
Helen R Gosselt, Jette A van Lint, Leanne J Kosse, Phyllis I Spuls, Harald E Vonkeman, Sander W Tas, Frank Hoentjen, Michael T Nurmohamed, Bart J F van den Bemt, Martijn Bastiaan Adriaan van Doorn, Naomi T Jessurun
Sex differences in adverse drug reactions from Adalimumab and etanercept in patients with inflammatory rheumatic diseases. Expert opinion on drug safety (2023)
Henrike J Westerink, Leanne J Kosse, Naomi T Jessurun, Astrid van Tubergen, Harald E Vonkeman, Michael T Nurmohamed, Bart J F van den Bemt, Marieke de Vries
Patients' and health-care professionals' perspectives on adverse drug reaction burden attributed to the use of biological DMARDs: a qualitative study. Expert opinion on drug safety (2022)
Lieke H Roest, Leanne J Kosse, Jette A van Lint, Helen R Gosselt, Joep H G Scholl, Eugene P van Puijenbroek, Harald E Vonkeman, Sander W Tas, Michael T Nurmohamed, Bart J F van den Bemt, Naomi T Jessurun
Disease-specific ADRs of TNF-α inhibitors as reported by patients with inflammatory rheumatic diseases: a registry-based prospective multicenter cohort study. Expert opinion on drug safety (2022)